Allergy Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Allergy Type (Allergic Asthma, Cat Dander Allergy, Grass Pollen Hypersensitivity, Peanut Hypersensitivity, Seasonal Allergic Rhinitis, Tree Pollen Hypersensitivity), By Vaccine Type (Cat Allergy Vaccine, House Dust Mite Allergy Vaccine, Injectable MPL Allergy Vaccine, Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine), By Application (HIV, Oncology, Respiratory), By End User (Homecare, Hospitals, Specialty Clinics, Others), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 1.42 Billion
CAGR (2026-2031)	8.29%
Fastest Growing Segment	Seasonal Allergic Rhinitis
Largest Market	North America
Market Size (2031)	USD 2.29 Billion

Market Overview

The Global Allergy Vaccine Market will grow from USD 1.42 Billion in 2025 to USD 2.29 Billion by 2031 at a 8.29% CAGR. Allergy vaccines, technically referred to as allergen immunotherapy, are therapeutic interventions designed to modify the immune system's response by administering gradually increasing doses of a specific allergen to induce long-term tolerance. The primary drivers sustaining market growth include the rapidly increasing global incidence of chronic allergic respiratory diseases and environmental shifts such as climate change, which are prolonging pollen seasons and intensifying allergen exposure. According to the Asthma and Allergy Foundation of America, in 2024, allergic conditions affected over 100 million people in the United States, underscoring the critical need for disease-modifying treatments that address the root cause of these pathologies rather than merely alleviating symptoms.

Despite the strong demand, the market encounters a significant challenge regarding patient adherence and the extensive duration of treatment required for efficacy. The commitment needed for multi-year regimens, whether through frequent subcutaneous injections or daily sublingual administration, often leads to high discontinuation rates, thereby impeding the broader adoption and revenue potential of these immunotherapeutic solutions.

Key Market Drivers

The escalating global incidence of chronic allergic respiratory and food disorders stands as the primary catalyst propelling the Global Allergy Vaccine Market. Rapid urbanization and rising environmental pollution are intensifying sensitization rates, driving an urgent requirement for long-term immunotherapeutic interventions beyond temporary symptom management. This surge is particularly evident in adult populations, creating a substantial demographic for novel desensitization strategies. According to the Food Standards Agency, May 2024, in the 'Patterns and Prevalence of Adult Food Allergy' report, approximately 6% of the adult population in the United Kingdom now has a clinically confirmed food allergy, representing a significantly expanded addressable market for emerging vaccine candidates.

Concurrently, growing regulatory approvals for convenient Sublingual Immunotherapy (SLIT) formulations are reshaping the treatment landscape by addressing critical adherence challenges associated with traditional subcutaneous injections. Patients and healthcare providers are increasingly favoring these non-invasive, home-administered tablets, which minimize the burden of frequent clinic visits and improve therapy completion rates. This shift in delivery preference is translating into tangible commercial success for major manufacturers. According to ALK-Abelló, February 2024, in the 'Annual Report 2023', sales of its allergy immunotherapy tablets increased by 11% in local currencies, highlighting the accelerated adoption of these patient-friendly solutions. This demand trajectory is further reinforced by pediatric vulnerabilities; according to Imperial College London, in 2024, the prevalence of food allergy in preschool-aged children reached 4%, signaling a sustained, long-term need for effective disease-modifying therapies across all age groups.

Download Free Sample Report

Key Market Challenges

The significant challenge hampering the growth of the Global Allergy Vaccine Market is the difficulty in ensuring patient adherence to the extensive and demanding treatment regimens required for efficacy. Allergy vaccines, or allergen immunotherapy, necessitate a multi-year commitment, typically spanning three to five years, involving either frequent subcutaneous injections or daily sublingual doses. This prolonged duration creates a substantial burden on patients, leading to "treatment fatigue" where individuals abandon therapy before achieving long-term tolerance. Consequently, high discontinuation rates directly reduce the recurring revenue streams for manufacturers and limit the overall market expansion, as the full therapeutic value—and financial return—is realized only through course completion.

The impact of this attrition is underscored by recent clinical data. According to the American College of Allergy, Asthma & Immunology (ACAAI), in 2024, a longitudinal study presented at their Annual Scientific Meeting revealed that 42.8% of patients discontinued immunotherapy over a five-year period. Such statistics highlight the fragility of the patient pipeline; when nearly half of the initiated patients fail to complete the full regimen, the market’s potential addressable audience effectively shrinks. This pattern of non-compliance not only diminishes direct sales but also instills hesitation among healthcare providers to prescribe these therapies, fearing that the long-term investment of time and resources will not yield the desired clinical outcomes for their patients.

Key Market Trends

Advancements in Virus-Like Particle (VLP) Vaccine Platforms are redefining allergy treatment by offering short-course immunomodulation that overcomes the safety and duration limitations of traditional extracts. These candidates use recombinant technology to enhance immune recognition, potentially condensing multi-year protocols into brief regimens. This progress is evident in recent clinical results; according to Allergy Therapeutics, December 2024, in the 'Positive Interim Data from PROTECT Trial' announcement, patients treated with their VLP Peanut candidate showed a 48% reduction in wheal size after skin-prick testing, compared to an 8% reduction in the placebo group. This data underscores the potential of VLP platforms to deliver rapid desensitization and ensure better adherence.

The Development of Epicutaneous Immunotherapy Patches is concurrently reshaping the sector, specifically for pediatric food allergies requiring non-invasive solutions. By utilizing the skin’s immune system to induce tolerance, these patches minimize anaphylactic risks associated with oral or injectable routes. Commercialization efforts are intensifying; according to DBV Technologies, October 2024, in the 'Positive Regulatory Updates for the Viaskin Peanut Patch' release, the company enrolled a total of 654 subjects in its pivotal VITESSE Phase 3 trial. Such development confirms the industry's pivot toward skin-based delivery systems to capture the substantial demand within the food allergy segment.

Segmental Insights

The Seasonal Allergic Rhinitis segment represents the fastest-growing category in the Global Allergy Vaccine Market, driven by the increasing incidence of pollen-induced respiratory conditions. This growth is largely attributed to the rising adoption of sublingual immunotherapy tablets, which offer a convenient, non-invasive alternative to traditional subcutaneous injections. Continuous product approvals by agencies such as the U.S. Food and Drug Administration for specific grass and ragweed pollen treatments have significantly enhanced patient accessibility. As environmental factors prolong pollen seasons, the demand for these targeted immunotherapies continues to rise, securing the segment's rapid expansion.

Regional Insights

North America maintains a leading position in the global allergy vaccine market, driven by a high prevalence of allergic disorders and substantial healthcare spending. The region benefits from a well-established medical infrastructure and the presence of key pharmaceutical manufacturers that ensure widespread product availability. Additionally, supportive regulatory frameworks provided by agencies like the U.S. Food and Drug Administration (FDA) accelerate the approval of new immunotherapies. Comprehensive reimbursement policies and rising patient awareness regarding long-term allergy management further reinforce North America's dominance in this industry.

Recent Developments

• In December 2024, ALK-Abelló announced that its sublingual allergy immunotherapy tablet, marketed as Acarizax, had received approval in Europe for use in children aged five to eleven years suffering from house dust mite allergy. This regulatory clearance expanded the approved patient group for the treatment, which was previously limited to adolescents and adults. The approval provided a new therapeutic option for younger pediatric patients, designed to treat the underlying cause of the allergy rather than just the symptoms. This development represented a key advancement in the company’s strategy to broaden the global reach of its respiratory allergy immunotherapy portfolio and improve care for children with persistent allergic rhinitis.
• In October 2024, Aravax, a clinical-stage biotechnology company, announced the completion of patient recruitment for its Phase 2 study of PVX108, a novel precision immunotherapy designed for the treatment of peanut allergy. The trial enrolled 95 participants across multiple sites in the United States and Australia, specifically targeting children and adolescents. PVX108 utilizes engineered peptides to precisely target T-cells and reverse the course of allergic disease without containing whole peanut proteins, thereby aiming to minimize the risk of severe side effects during administration. The company anticipates reporting headline results from this study in the first half of 2026, marking a significant progression in the development of next-generation food allergy treatments.
• In July 2024, Stallergenes Greer announced that the U.S. Food and Drug Administration had approved an extension of the indication for Palforzia to include the treatment of toddlers aged one to three years with a confirmed diagnosis of peanut allergy. This regulatory decision expanded the addressable patient population for the oral immunotherapy, which was previously authorized only for individuals aged four through seventeen years. The approval was based on positive results from the Phase 3 POSEIDON study, which evaluated the efficacy and safety of the treatment in this younger demographic. The company highlighted that this approval addressed a critical unmet medical need for early intervention in young children suffering from peanut allergies.
• In February 2024, Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration had granted approval for Xolair (omalizumab) to reduce allergic reactions, including anaphylaxis, that may occur with accidental exposure to one or more foods in adult and pediatric patients aged one year and older. This milestone established the drug as the first and only medicine approved for this specific indication in the food allergy market. The approval was supported by data from the Phase III OUtMATCH study, which showed that a statistically significant proportion of patients treated with the drug could tolerate small amounts of peanut, milk, egg, and cashew without an allergic reaction compared to placebo.

Key Market Players

• Stallergenes Greer PLC
• Allergy Therapeutics PLC
• HAL Allergy BV
• Jubilant HollisterStier Allergy
• Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
• Dermapharm AG
• Merck KGaA
• Aimmune Therapeutics Inc.
• Biomay AG

By Allergy Type	By Vaccine Type	By Application	By End User	By Region
Allergic Asthma Cat Dander Allergy Grass Pollen Hypersensitivity Peanut Hypersensitivity Seasonal Allergic Rhinitis Tree Pollen Hypersensitivity	Cat Allergy Vaccine House Dust Mite Allergy Vaccine Injectable MPL Allergy Vaccine Peanut Allergy Vaccine Ragweed Allergy Immunotherapy Vaccine	HIV Oncology Respiratory	Homecare Hospitals Specialty Clinics Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Allergy Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Allergy Vaccine Market , By Allergy Type:

• Allergic Asthma
• Cat Dander Allergy
• Grass Pollen Hypersensitivity
• Peanut Hypersensitivity
• Seasonal Allergic Rhinitis
• Tree Pollen Hypersensitivity

• Allergy Vaccine Market , By Vaccine Type:

• Cat Allergy Vaccine
• House Dust Mite Allergy Vaccine
• Injectable MPL Allergy Vaccine
• Peanut Allergy Vaccine
• Ragweed Allergy Immunotherapy Vaccine

• Allergy Vaccine Market , By Application:

• HIV
• Oncology
• Respiratory

• Allergy Vaccine Market , By End User:

• Homecare
• Hospitals
• Specialty Clinics
• Others

• Allergy Vaccine Market , By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE